Physician profile
Jacquelyn Sullivan
NPI 1306518477
$1,907.98
in general payments reported to CMS, 2019-2025
16 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $572 · 2023: $393 · 2024: $468 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Education: $13.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.14 |
| Education | $13.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.11 | 2021-2025 | |
| Celgene Corporation | $258.62 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $210.68 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $194.20 | 2021-2024 | Entyvio |
| Ardelyx, INC. | $150.10 | 2023-2024 | Ibsrela |
| Galderma Laboratories, L.P. | $82.37 | 2025 | |
| Intercept Pharmaceuticals, INC. | $75.34 | 2021-2024 | Ocaliva |
| Innovation Technologies INC | $55.77 | 2025 | Irrisept |
| Janssen Scientific Affairs, LLC | $46.48 | 2022 | |
| Genzyme Corporation | $41.13 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 2022 | |
| Pfizer INC. | $23.04 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $20.18 | 2025 | |
| Motiva USA, LLC | $20.15 | 2025 | |
| Lilly USA, LLC | $15.40 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $13.41 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.